Lee Chan Henry Buys Shares of ONC
Lee Chan Henry, SVP and General Counsel at ONC, acquired 45,071 shares.
Key Points
- Lee Chan Henry, SVP at ONC, purchased 45,071 shares on June 11, 2026, with the stock trading at $264.48.
- Shares of ONC were trading near $264.48, with analysts maintaining strong buy ratings and targets up to $436.
- Other institutional investors like Baker Bros. Advisors held over 8.7 million shares, while Citadel Advisors increased its holdings significantly.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Lee Chan Henry, the Senior Vice President and General Counsel at ONC, bought 45,071 shares of the company on June 11, 2026. This insider purchase occurred with the stock priced at $264.48 per share.
Other Institutional Activity in ONC
Baker Bros. Advisors LP maintained its position in ONC with 8,799,053 shares valued at approximately $2.61 billion. Primecap Management trimmed its holdings slightly by 5,400 shares, bringing its total to 4,975,181 shares worth about $1.48 billion. Capital International Investors reduced its stake by 955,140 shares, ending with 4,158,726 shares valued at $1.23 billion. Meanwhile, Citadel Advisors LLC nearly doubled its holdings, adding 516,719 shares to reach a total of 1,050,236 shares, valued at $306.6 million.
BeOne Medicines AG Stock Down 27.9%
ONC shares were trading near $264.48 at the time of the insider purchase. Analysts have shown confidence in the stock, with RBC Capital maintaining a 'buy' rating and setting a price target of $436 on June 2, 2026. Other analysts, including Leerink Partners and Guggenheim, have also maintained 'buy' ratings with targets of $367 and $420, respectively.
$ONC stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at BeOne Medicines AG
Several insiders, including Shalini Sharp and Xiaodong Wang, made significant purchases on June 11, 2026. Shalini Sharp acquired 18,980 shares, while Xiaodong Wang bought 193,492 shares in one transaction and 99,892 shares in another. Charles Lazelle Sawyers added 18,980 shares to his holdings. These purchases were not part of any pre-planned trading programs.
Analysts Set New Price Targets
On June 2, 2026, RBC Capital maintained its 'buy' rating on ONC with a price target of $436. Earlier, on May 15, 2026, Leerink Partners also maintained a 'buy' rating, setting a target of $367. Guggenheim and Barclays shared similar sentiments, maintaining 'buy' ratings with targets of $420 and $409, respectively. Truist Securities reiterated its 'buy' rating with a target of $413 on May 7, 2026.
Bottom Line
The recent insider buying activity by Lee Chan Henry and other executives at ONC reflects a strong belief in the company's future prospects. While insider transactions are only one piece of the puzzle, they can be a signal of confidence in the company's direction. Investors often track such moves to gauge market sentiment. However, it's important to remember that insider purchases are just part of the broader investment picture.
Get BeOne Medicines AG alerts
New 13F filings, insider trades, and analyst moves on $ONC, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.